罗沙司他对肾性贫血患者贫血相关指标及炎症介质的影响

Effects of Roxadustat on Anemia-related Indexes and Inflammatory Factors in Patients with Renal Anemia

目的探讨罗沙司他对肾性贫血患者贫血相关指标及炎症介质的影响。方法选取2018年12月至2019年12月在沈阳医学院附属中心医院肾内科就诊的78例肾性贫血患者作为研究对象,随机分为观察组40例与对照组38例。观察组患者在透析前1 h或透析后2 h给予罗沙司他口服,对照组患者皮下注射促红细胞生成素,两组治疗4周。比较两组患者贫血相关指标和炎症介质水平。结果治疗前,两组患者贫血相关指标和炎症介质水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者血细胞比容(HCT)、转铁蛋白饱和度(TSAT)、血清铁蛋白(SF)、血红蛋白(Hb)明显升高,且观察组患者HCT、TSAT、SF、Hb明显高于对照组,差异有统计学意义(P<0.05);治疗后,两组患者白细胞介素-6(IL-6)、C反应蛋白(CRP)水平明显下降,且观察组患者IL-6、CRP水平明显低于对照组,差异有统计学意义(P<0.05)。结论使用罗沙司他治疗肾性贫血患者,贫血相关指标和炎症介质水平改善优于使用传统促红细胞生成素治疗。

Objective To explore the effect of rosastat on anemia-related indicators and inflammatory mediators in patients with renal anemia. Methods A total of 78 patients with renal anemia admitted to the Department of Nephrology in Central Hospital Affiliated to Shenyang Medical College from December 2018 to December 2019 were selected as the research subjects, and were randomly divided into an observation group with 40 cases and a control group with 38 cases. Patients in the observation group were given oral roxadustat 1 h before dialysis or 2 h after dialysis, and patients in the control group were injected subcutaneously with erythropoietin. Both groups were treated for 4 weeks. The anemia-related indexes and inflammatory factors of patients in the 2 groups were compared. Results Before treatment, there were no statistically significant differences in anemia-related indexes and inflammatory factors between the 2 groups(P>0.05). After treatment, the hematocrit(HCT), transferrin saturation(TSAT), serum ferritin(SF), and hemoglobin(Hb) of the 2 groups of patients were significantly increased, and the HCT, TSAT, SF, and Hb of the observation group were significantly higher than those of the control group, the difference was statistically significant(P<0.05);after treatment, the levels of interleukin-6(IL-6) and C-reactive protein(CRP) in the 2 groups were significantly decreased, and the levels of IL-6 and CRP in the observation group were significantly lower than the control group, the difference was statistically significant(P<0.05). Conclusion When patients with renal anemia are treated with roxadustat, the anemia-related indexes and inflammatory factors were improved, comparing to those treated with traditional erythropoietin.